Synthesis and amyloid binding properties of rhenium complexes: Preliminary progress toward a reagent for SPECT imaging of Alzheimer's disease brain

Journal of Medicinal Chemistry

Volumn 42, Issue 15, 1999, Pages 2805-2815

  Zhen, Weiguo ^a,b,c   Han, Hogyu ^b,d   Anguiano, Magdalena ^a,b   Lemere, Cynthia A ^a   Cho, Cheon Gyu ^a,b,e   Lansbury Jr , Peter T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c PERKINELMER INC   (United States)

^d Korea University   (South Korea)

^e Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CONGO RED; LIGAND; RHENIUM COMPLEX; TECHNETIUM;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; COGNITION; DIAGNOSTIC IMAGING; NERVE LESION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CEREBRAL CORTEX; COLORING AGENTS; CONGO RED; HUMANS; ORGANOMETALLIC COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; RHENIUM; STAINING AND LABELING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033614955     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990103w     Document Type: Article

References (56)

1. McKhann, G., et al. Clinical diagnosis of Alzheimer's disease: a report of the NINCDS-ADRDA Work Group, Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34, 939-944.
2. Weiner, M. F. Alzheimer's disease: diagnosis and treatment. Harvard Rev. Psychiatry 1997, 4, 306-316.
3. Selkoe, D. J. Amyloid β-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271, 18295-18298.
4. Yankner, B. A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16, 921-932.
5. Cummings, B. J.; Pike, C. J.; Shankle, R.; Cotman, C. W. β-Amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol. Aging 1996, 17, 921-933.
6. Lansbury, P. T., Jr. A Reductionist view of Alzheimer's disease. Acc. Chem. Res. 1996, 29, 317-321.
7. Selkoe, D. Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997, 275, 630-631.
8. Teller, J. K.; et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med. 1996, 2, 93-95.
9. Lemere, C. A.; et al. Sequence of deposition of heterogeneous amyloid β-peptides and Apo E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol. Disease 1996, 3, 16-32.
10. Lemere, C. A.; et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nature Med. 1996, 2, 1146-1148.
11. Scheuner, D.; et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 1996, 2, 864-870.
12. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32, 4693-4697.
13. Greenberg, S. M.; Rebeck, G. W.; Vonsattel, J. P. G.; Gomez-Isla, T.; Hyman, B. T. Apolipoprotein E ∈4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 1995, 38, 254-259.
14. Gearing, M.; Mori, H.; Mirra, S. S. Aβ peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann. Neurol. 1996, 39, 395-399.
15. Hyman, B. T.; et al. Quantitative analysis of senile plaques in Alzheimer's disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3586-3590.
16. Nicoll, J. A. R.; Roberts, G. W.; Graham, D. I. Apolipoprotein E E4 allele is associated with deposition of amyloid β-protein following head injury. Nature Med. 1995, 1, 135-137.
17. Games, D.; et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995, 373, 523-527.
18. Hsiao, K.; et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274, 99-102.
19. 123I-labeled serum amyloid P component and SPET. Nucl. Med. Commun. 1996, 17, 929-933.
20. Klunk, W. E.; Debnath, M. L.; Pettegrew, J. W. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol. Aging 1994, 15, 691-698.
21. Klunk, W. E.; Debnath, M. L.; Pettegrew, J. W. Chrysamine-G Binding to Alzheimer and Control Brain: Autopsy Study of a New Amyloid Probe. Neurobiol. Aging 1995, 541-548.
22. Ashburn, T. T.; Han, H.; McGuinness, B. F.; Lansbury, P. T. Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem. Biol. 1996, 3, 351-358.
23. Han, H.; Cho, C.-G.; Lansbury, P. T., Jr. Technetium complexes for the quantitation of brain amyloid. J. Am. Chem. Soc. 1996, 118, 4506-4507.
24. Majocha, R.; Marotta, C. A.; Zain, S. Patent #5,231,000, 1993.
25. 125I-Labeled β-amyloid peptide Aβ1-40 through the blood-brain barrier and binding to Alzheimer's disease amyloid of the Aβ1-40/vector complex. Proc. Natl. Acad. Sci. U.S.A. 1985, 92, 10227-10231.
26. Horn, R. K.; Katzenellenbogen, J. A. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl. Med. Biol. 1997, 24, 485-498.
27. Tubis, M.; Blahd, W. H.; Nordyke, R. A. The preparation and use of radioiodinated Congo Red in detecting amyloidosis. J. Am. Pharm. Assoc. 1960, 49, 422-425.
28. Meltzer, P. C.; et al. A Technetium-99m SPECT Imaging Agent Which Targets the Dopamine Transporter in Primate Brain. J. Med. Chem. 1997, 40, 1835-1844.
29. Kung, H. F.; Molnar, M.; Billings, J.; Wicks, R.; Blau, M. Synthesis and Biodistribution of Neutral Lipid-Soluble Tc-99m Complexes that cross the Blood-Brain Barrier. J. Nucl. Med. 1984, 25, 326-332.
30. Dischino, D. D.; Welch, M. J.; Kilbourn, M. R.; Raichle, M. E. Relationship Between Lipophilicity and Brain Extraction of C-11-Labeled Radiopharmaceuticals. J. Nucl. Med. 1983, 24, 1030-1038.
31. Neirinckx, R. D.; et al. Technetium-99m d,l-HM-PAO: A New Radiopharmaceutical for SPECT Imaging of regional Cerebral Blood Perfusion. J. Nucl. Med. 1987, 28, 191-202.
32. Abrams, M. J.; Murrer, B. A. Metal compounds in therapy and diagnosis. Science 1993, 261, 725-730.
33. VO (M = Tc, Re) amine-thiol complexes containing a pendant phenylpiperidine group. Inorg. Chem. 1993, 32, 3114-3124.
34. Davison, A.; Sohn, M.; Orvig, C.; Jones, A. G.; LaTegola, M. R. A tetradentate ligand designed specifically to coordinate technetium. J. Nucl. Med. 1979, 20, 641.
35. 2 core. Inorg. Chem. 1981, 20, 1629-1632.
36. DiZio, J. P.; Fiaschi, R.; Davison, A.; Jones, A.; Katzenellenbogen, J. A. Progestins-rhenium complexes: metal-labeled steroids with receptor binding activity, potential receptor-directed agents for diagnostic imaging therapy. Bioconjugate Chem. 1991, 2, 353-366.
37. DiZio, J. P.; et al. Technetium and rhenium labeled progestins: synthesis, receptor binding and in vivo distribution of an 11β-substituted progestin labeled with technetium-99 and rhenium-186. J. Nucl. Med. 1992, 33, 558-569.
38. Gustavson, L. M.; Rao, T. N.; Jones, D. S.; Fritzberg, A. R. Synthesis of a new class of Tc chelating agents: monoamine-monoamide (MAMA) ligands. Tetrahedron Lett. 1991, 32, 5485-5488.
39. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996, 22, 239-246.
40. O'Neil, J. P.; Wilson, S. R.; Katzenellenbogen, J. A. Preparation and structural characterization of monoamine-monoamide bis(thiol) oxo complexes of technetium (V) and rhenium (V). Inorg. Chem. 1994, 33, 319-323.
41. Kung, H. F.; et al. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur. J. Nucl. Med. 1996, 23, 1527-1530.
42. Meegalla, S. K.; et al. Synthesis and Characterization of Technetium-99m-Labeled Tropanes as Dopamine Transporter-Imaging Agents. J. Med. Chem. 1997, 40, 9-17.
43. Wolfe, J. A. Ph.D. Thesis, MIT, Cambridge, MA 02139, 1991.
44. Connolly, B. A. Chemical synthesis of oligonucleotides containing a free sulphydryl group and subsequent attachment of thiol specific probes. Nucleic Acids Res. 1985, 13, 4485-4502.
45. Mag, M.; Luking, S.; Engels, J. W. Synthesis and selective cleavage of an oligonucleotide containing a bridged internucleotide 5′-phosphorothioate linkage. Nucleic Acids Res. 1991, 19, 1437-1441.
46. Tomiyama, T.; et al. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem. Biophys. Res. Commun. 1994, 204, 76-83.
47. Tomiyama, T.; et al. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues. J. Biol. Chem. 1994, 269, 10205-10208.
48. Soto, C.; Castano, E. M.; Kumar, R. A.; Beavis, R. C.; Frangione, B. Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Neurosci. Lett. 1995, 200, 105-108.
49. Lever, S. Z.; Baidoo, K. E.; Mahmood, A. Structural proof of syn/ anti isomerism in N-alkylated diamine dithiol complexes of technetium. Inorg. Chim. Acta 1990, 176, 183-184.
50. Levin, V. Relationship of Octanol/Water Partition Coefficient and Molecular Weight to Rat Brain Capillary Permeability. J. Med. Chem. 1980, 23, 682-684.
51. Lansbury, P. T. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Curr. Opin. Chem. Biol. 1997, 1, 260-267.
52. Reid, T. M.; Morton, K. C.; Wang, C. Y.; King, C. M. Conversion of Congo red and 2-azoxyfluorene to mutagens following in vitro reduction by whole-cell rat cecal bacteria. Mutat. Res. 1983, 117, 105-112.
53. Kelly, J. W.; Lansbury, P. T., Jr. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid: Int. J. Exp. Clin. Invest. 1994, 1, 186-205.
54. Klunk, W. E.; Pettegrew, J. W.; Abraham, D. J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 1989, 37, 1273-1281.
55. Bennett, J. J.; Yamamura, H. I. Neurotransmitter Hormone, or Drug Receptor Binding Methods. In Neurotransmitter Receptor Binding; Yamamura, H. I., et al., Eds.; Raven Press: New York, 1985; pp 61-89.
56. Lemere, C. A.; et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain: An immunocytochemical study. Am. J. Pathol. 1995, 146, 848-860.